TITLE

ROCHE COMPLETES ACQUISITON OF ARIUS RESEARCH

PUB. DATE
November 2008
SOURCE
Worldwide Biotech;Nov2008, Vol. 20 Issue 11, p1
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on the acquisition of the100% of the issued and outstanding warrants of Arius Research by biotechnology company Roche. The Ontario Supreme Court in Canada has approved on September 19, 2008, the Plan of Arrangement previously approved by the security holders. Arius is the developer of a proprietary antibody platform called FunctionFIRST.
ACCESSION #
34959884

 

Related Articles

  • Roche to Acquire Two Firms in North America. Ramesh, Deepti // Chemical Week;8/4/2008, Vol. 170 Issue 24, p21 

    The article reports on the plan of Roche to acquire two biotechnology firms in North America. The company says it has agreed in purchase biotech company Arius Research for about C$191 million, and that it has signed a separate deal to acquire biopharmaceutical company Mirus Bio for $125 million....

  • Roche Continues on a Roll; Getting Arius for $190M. Hollingsworth, Catherine // BioWorld Today;7/24/2008, Vol. 19 Issue 143, p1 

    The article reports on the move of Roche Holding AG to acquire antibody screening company Arius Research Inc. of Toronto, Ontario for about C$191 million (US$189.2 million). It notes that the all-cash deal is expected to close in the third quarter of 2008. Roche plans to keep Arius' site in...

  • Roche on a Roll; Getting Arius for $190M.  // Bioworld Week;7/28/2008, Vol. 16 Issue 30, p4 

    The article reports on the acquisition of antibody screening company Arius Research Inc. by Roche Holding AG for $189.2 million in Toronto, Ontario. It indicates that the Toronto location would serve as a center for the discovery of innovative biotherapeutics, focusing on oncology and...

  • Roche completes acquisition of outstanding shares of Arius.  // Medical Device Daily;9/25/2008, Vol. 12 Issue 205, p5 

    The article reports that Roche has completed the acquisition of the outstanding shares and warrants of Arius Research. A Plan of Arrangement, also previously approved by the security holders, was approved by the Ontario Superior Court on September 19, 2008. All other conditions of closing have...

  • Genentech Again Nixes Roche Takeover Offer.  // BioWorld Today;2/24/2009, Vol. 20 Issue 35, p3 

    The article reports on the decision of a special Genentech Inc. board committee to reject a takeover offer from Roche Holdings AG. The committee recommended against accepting Roche's hostile $44 billion buyout offer, citing Genentech's strong projected financial performance, among other reasons....

  • Pharma-Biotech M&As Pose Unique Challenges. Daks, Martin C. // njbiz;7/28/2008, Vol. 21 Issue 31, p9 

    The article discusses the unique challenges in the mergers and acquisitions of biotechnology firms. Unlike traditional mergers, a key difference in biotechnology may involve multiple joint development agreements with third parties for certain rights to specific projects. As in the merger of...

  • Deals, Deals, Deals.  // BioPharm International;Jul2003, Vol. 16 Issue 7, p8 

    Reports several deals in biotechnology industry in the U.S. as of July 2003. Acquisition of Roche of the global commercialization rights to Maxygen's portfolio of interferon alpha and beta variants; Development of Pall of customized 192-well plate sample preparation tool for the Human Genome...

  • Goodbye Genentech, But No Obit for Biotech Yet, Please. Boggs, Jennifer // BioWorld Today;3/16/2009, Vol. 20 Issue 49, p1 

    The article focuses on the possible impact of the merger between Roche Holdings AG and Genentech Inc. on the biotechnology industry. In the said deal, Roche agreed to acquire the remaining shares of Genentech priced at $95 per share. Some speculate that the merger could have a large impact on...

  • Roche launches hostile bid for Genentech shares.  // Nature;2/5/2009, Vol. 457 Issue 7230, p648 

    The article discusses the hostile bid by the Swiss pharmaceutical company Roche to capture a larger percentage of the U.S. biotechnology company Genentech than it already owns. Roche's request was initially denied by Genentech who claimed that the offer was too low. Topics include how the global...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics